Key insights
- Novo Nordisk's CagriSema trial REDEFINE-9 showed that a higher dose (1.7mg/1.7mg) resulted in less weight loss compared to a lower dose (1.0mg/1.0mg). The higher dose also exhibited significantly higher rates of nausea (66%) and vomiting (32%), with placebo-adjusted rates of 40% and 25% respectively. These adverse event rates are considerably higher than those reported for competing drugs like tirzepatide and retatrutide, suggesting a potential tolerability issue for CagriSema.

CagriSema is really the drug that keeps on giving. After disappointing investors with the nuclear bomb results from REDEFINE-1, the stock has been in a 60% decline since then. Then the absolute cinema results from REDEFINE-4 and REIMAGINE-4 put this drug 6 feet under as Novo themselves literally proved that Mounjaro/Zepbound was better than their own drug in a head-to-head. Their own trial proved their competitor was better. Incredible. Text books will be written about these trials... Well today at Obesity Week, they expanded on the results from REDEFINE-9 where once again, it's a comedy of errors. Top line results from this trial was already released, but they BURIED the 1.7mg/1.7mg results in the fine print. Why? Well, because upping the dose gave LESS weight loss. You literally can't make this shit up... And it gets better, for the 1.7mg/1.7mg dose nausea occurred in 66% of patients and vomiting 32%!!! Even if you placebo adjust those numbers it's 40% nausea and 25% vomiting. The 1.0mg/1.0mg was not much better with 62% and 27% nausea and vomiting (placebo adjusted 36% and 20%). These are horrendous numbers. For example, tirzepatide at max dose, gets 21.5% placebo adjusted nausea, and 10.5% placebo adjusted vomiting (SURMOUNT-1). And even retatrutide at max dose gets 27.6% and 20.5% placebo adjusted nausea and vomiting (TRIUMPH-1). And these numbers are no fluke, in REDEFINE-1, the placebo adjusted nausea and vomiting was 42.4% and 22%. CagriSema has a TOLERABILITY problem and Novo knows it! They bury the adverse event data. For example, the NEJM article for REDEFINE-1 BURIES the adverse event data in a supplementary chart. They reported ALL GI AE's as a single number in the main article. Pay no attention to the man behind the curtain! They STILL have not shown the adverse event data from REDEFINE-4 and REIMAGINE-4 because it would prove once and for all that their drug is less efficacious AND less tolerable. Literally no reason to use it at all... So the big question is why. Why is CagriSema so bad in these trials? The answer is simple, an inherently less tolerable drug in a trial where they used flexible dosing. The Cagri in CagriSema is cagrilintide which is a DACRA, dual amylin calcitonin receptor agonist. Despite Novo PR that says calcitonin agonism is a feature not a bug, that's not really the case. Calcitonin agonism is KNOWN to be emetic. It CAUSES nausea and vomiting and it's paired with a drug, semaglutide, that is ALSO known to cause nausea and vomiting. It's a wild combo for Novo to CONTINUE to pursue as their next drug zenagamtide is ALSO a DACRA! these drugs will be vomitfests and Novo is stuck in a sunk cost fallacy. They will spend millions bringing them to market, only to see real world results exactly like REDEFINE-4 and REIMAGINE-4... So is there any upside to this drug? Basically NO... Do your own research before investing in these value traps. There is a reason this company trades at such a low multiple. Their pipeline stinks and their near term assets are facing hurricane headwinds as I have described above. The professional analysts know this as well, that's why there are so few BUY recommendations. The $NVO bagholders? They get all their info from social media, not PubMed...